Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2024

Summary of Significant Accounting Policies

Schedule of accounts receivable allowance for credit loss

The Company's allowance for credit losses is as follows (in thousands):


	Year Ended December 31,
	2024		2023		2022
Beginning balance	$	1,092	$	1,225	$	791
Adoption of ASU 2016-13		—		149		—
Changes to the provision		516		705		1,158
Accounts written off		(281)		(987)		(724)
Ending balance	$	1,327	$	1,092	$	1,225

Schedule of property, plant and equipment useful life


Property, Equipment, and Software Asset Type	Estimated Useful Lives
Software development costs	3 years
Computers	3 years
Furniture, fixtures, and equipment	5 years
Leasehold improvements	Shorter of estimated economic useful life or remaining lease term

Schedule of remaining performance obligation

For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of December 31, 2024 was $48.8 million and is expected to be recognized based on the below schedule (in thousands).


Remaining Performance Obligation	December 31, 2024
2025	$	28,633
2026		15,969
2027		3,995
2028		131
2029		28
Total	$	48,756

Schedule of total net revenues by geographic region

The Company’s total revenues by geographic region, based on the domicile of the Company’s respective business operations supporting the end software user, is presented in the following table (in thousands):


	Year Ended December 31,
	2024				2023				2022
Geographic Region	Amount		Percent		Amount		Percent		Amount		Percent
Americas	$	125,803	62.4	%	$	108,506	62.1	%	$	95,122	63.3	%
Europe, Middle East, and Africa (EMEA)		32,351	16.0	%		26,122	15.0	%		20,051	13.3	%
Asia Pacific (APAC)		43,457	21.6	%		39,907	22.9	%		35,176	23.4	%
Total revenues (a)	$	201,611	100.0	%	$	174,535	100.0	%	$	150,349	100.0	%

(a)	Includes revenues from clients supported in the United States of $122.4 million, $104.5 million, and $92.8 million for the years ended December 31, 2024, 2023, and 2022, respectively.

Enfusion, Inc. 10-K